
The study analyzed circulating biomarkers in atrial fibrillation (AF) patients to assess their association with heart failure (HF) outcomes. The study included 8,765 patients from the ENGAGE AF-TIMI 48 trial, and elevated levels of high-sensitivity troponin T (hsTnT), N-terminal B-type natriuretic peptide (NT-proBNP), and growth differentiation factor-15 (GDF-15) at baseline and 12 months were associated with a higher risk of hospitalization for HF and HF death. The associations were consistent regardless of an HF or ejection fraction (EF) history. The study suggests that serial measurement of these biomarkers may help identify patients with AF at higher risk for HF outcomes.
Like
Save
Share